Activating Stilled Lives: The Aesthetics and Politics of Specimens on Display; International Conference at the Department of History of Art, UCL


This exciting conference--free and open to all!--just announced! Looks like a good one; so wish I could go!

Cultures of Preservation
Prepared specimens appear in many guises: as monstrous or typical organs preserved in formaldehyde and kept in glass jars not unlike pickled food, as stained and fixed tissue slices, or as skilfully arranged mounted animals. They may be found in cabinets of curiosities, in the laboratories of histologists, in anatomy theatres or in natural history collections, but nowadays equally in art galleries, the shop windows of fashionable boutiques, or horror films. This research network is concerned with such kinds of preserved natural objects, in particular with anatomical wet or dry preparations and taxidermy. It explorses the hybrid status of these objects between nature and representation, art and science and studies their fabrication, history and display.

The network is a collaboration between the UCL Department of History of Art, UCL collections, in particular the Grant Museum of Zoology, the Hunterian Museum, London and the Natural History Museum, London.

Activating Stilled Lives: The Aesthetics and Politics of Specimens on Display
International conference at the Department of History of Art, UCL
Thursday 17 May - Friday 18 May 2012

The past twenty years saw an explosion of exhibitions fathoming the relations between art and science as well as numerous refurbishments of natural history or former colonial museums. Many of these displays and gallery transformations mobilised specimens, be it taxidermied animals or preserved human body parts. Objects were put into new contexts opening up their meanings, others disappeared in storage or travelled back to the countries where they were once collected. The conference will address the challenges institutions face when dealing with formerly living entities and consider the aesthetics and politics of their display. The idea is to discuss the use of specimens in temporary exhibitions, museums or university collections and the role curators, art and artists have been playing in the transformation of these spaces. We also would like to consider how preserved specimens have changed through the altering contexts in which they have been displayed. One could name the initial transformation of organisms into objects, the more recent re-definition of pathological specimens as human remains, or the dramatic rearrangements that took place when natural history, anthropology or anatomy collections (many dating from the nineteenth century) were updated – coinciding with a shift in audiences, from specialists to a broader public. Often the historical displays were significantly altered, or even destroyed and replaced by „techy“ but at times also sentimentalised, „post-modern“ installations that still await a critical assessment.

Beyond that, the question of preservation shall be considered in a more expanded sense, as this subject area offers a unique opportunity to reflect more broadly on issues of conservation and their ethics and to raise a variety of questions such as: How and why do various cultures preserve elements of what is considered as nature? How does this relate to environmental notions of conservation and extinction? Should flawed specimens be disposed of? Can museums as a whole be considered cultural preserves? Should we preserve the preserves? And last but not least: Do we really need to embalm everything?

Confirmed speakers: Claude d'Anthenaise (Director, Musée de la chasse et de la nature, Paris), Steve Baker (Artist and Art Historian, Norfolk), Christine Borland (Artist, Glasgow), Mark Carnall (Curator, Grant Museum of Zoology, London), Nélia Dias (Anthropologist, Lisbon), Anke te Heesen (Museology / European Ethnology, Berlin), Petra Lange-Berndt (Art Historian, London), John MacKenzie (Professor Emeritus of Imperial History, Lancaster), Robert Marbury (Artist / Minnesota Association of Rogue Taxidermy, Baltimore), Angela Matyssek (Art Historian, Marburg / Maastricht), Lisa O'Sullivan (Curator, Science Museum/art-history/events/culture_of_preservation London), Hans-Jörg Rheinberger (Historian of Science, Berlin), Rose Marie San Juan (Art Historian, London), Johannes Vogel (Director, Museum für Naturkunde, Berlin)

Detailed programme: For further information please contact
Mechthild Fend m.fend(@)ucl.ac.uk or Petra Lange-Berndt p.lange-berndt(@)ucl.ac.uk

More information available here.

Source:
http://morbidanatomy.blogspot.com/feeds/posts/default?alt=rss

"Ouija: The Talking Board" A New Episode of The Midnight Archive, Featuring Mitch Horowitz

A new episode of The Midnight Archive--the web-based documentary series centered around Observatory--has just been uploaded and can be viewed above. Here is what the series creator--film-maker and many-time Observatory lecturer Ronni Thomas--has to say about this episode:

Episode 11 : Ouija: The Talking Board -- And we’re back - with the fascinating Mitch Horowitz (see Occult NY parts 1 and 2) and the incredible history of the Ouija Board. Learn about its early roots as a sort of ‘telegraph’ to the other side - to its evolution into the board game to outsell Monopoly. Get a haunting glimpse into some of the celebrities who used the board and learn about its ominous warning to poet Sylvia Plath. Its more than just a toy and a Morrissey song. So enjoy this latest installment and make sure to ‘like’ us on Facebook. Also for a more detailed history make sure to check out Mitch’s book Occult America (which can and should be purchased here).

For more on the series, to see former episodes, or to sign up for the mailing list and thus be alerted to future uploads, visit The Midnight Archive website by clicking here. You can also "like" it on Facebook--and be alerted in this way--by clicking here. You can find out more about the amazing work of Sigrid Sarda by clicking here.

Source:
http://morbidanatomy.blogspot.com/feeds/posts/default?alt=rss

Advocacy group linked to stem cell industry asks medical board for less-strict rule

By Mary Ann Roser

AMERICAN-STATESMAN STAFF

An Austin-based group funded mainly by a company that develops stem cell therapies is petitioning the Texas Medical Board for a less-strict rule on adult stem cells an issue the board has struggled with for more than a year.

The board will hold a hearing April 13 on its proposed rule, which would require doctors to get informed consent from patients before performing a stem cell procedure as well as approval from an institutional review board.

Such boards review research to protect patients and are overseen by the U.S. Food and Drug Administration.

At the meeting, the board must either adopt or pull down the much-revised rule, said Mari Robinson, executive director of the medical board.

The group, MedRebels Foundation, which seeks to raise awareness and educate the public about stem cells, will present its petition at the hearing. It has more than 2,500 signatures, many of them gathered near the company's Red River Street office during the South by Southwest Music Conference and Festival, Executive Director Shay McBurney said Friday. The office space is provided by SpineSmith and its parent, Celling Biosciences, which develops products and therapies using a person's own adult stem cells.

The petition asks the board not to put any additional restrictions on adult stem cells that are obtained from a patient's own body, provided they are used in the same medical procedure and not extensively processed or grown outside the body, frozen or stored.

"We were pretty amazed at how many people came and signed our petition," McBurney said.

MedRebels hopes the medical board recognizes that there are different types of stem cells, unlike its proposed rule, which "would classify all stem cells in the same bucket," said Matthew Murphy, a senior scientist at Celling Biosciences who spoke on behalf of MedRebels.

Go here to see the original:
Advocacy group linked to stem cell industry asks medical board for less-strict rule

Patient Beware: When Stem Cells Harm

Early in March 2012, 77-year-old Richard Poling entered a clinic in Bonita Springs, Fla., for a stem cell treatment to help with age-related heart and lung conditions.

Poling, an avid golfer and family man from Indiana, had sought several conventional therapies to alleviate his suffering with unsatisfactory results and was desperate for a treatment that would allow him to enjoy the pleasures of life again. Shortly after receiving his alleged treatment, however, Poling went into cardiac arrest at the clinic and died. According to investigators, the alleged stem cell treatment Poling received was not approved by the FDA.

According to multiple reports, the local cardiologist who conducted the treatment removed fat cells from Poling's abdomen and sent them to a lab that claimed to process and isolate adult stem cells from a patient's own fat. A few hours later, a second procedure was allegedly performed at the same clinic in which Poling had the stem cells injected back into his bloodstream for their regenerative properties. The entire process took one day, and during the hours between the procedures, Poling enjoyed lunch out with his family.

Poling was the second patient to die under the same doctor's care in the last two years after receiving the supposed stem cell therapy. The physician was already under order by the state of Florida to cease performing any further stem cell treatments pending further review, but the doctor allegedly continued performing various stem cell procedures -- until his license was revoked and suspended after Poling's death.

With all the marvels of modern medicine, there are still medical needs that remain unmet by our conventional health care system. When that happens, desperate people like Poling search for alternatives anywhere they can find them. One of these alternatives is stem cell therapy, a science that is no stranger to controversy.

The problem lies in that most stem cell therapies are not FDA-approved, and thus the market is under-regulated and consists of products that lack standardization and legitimacy. The lack of approved products has generated a gray market for stem cell therapeutics -- one that is dangerous and can be deadly.

Even though the United States has taken a passive approach to stem cell therapy as compared to its European and Asian counterparts, there are several U.S. companies vying for FDA approval as they develop stem cell therapies for indications such as heart disease, neurologic disorders and ophthalmologic diseases. While these companies spend hundreds of millions of dollars individually -- billions collectively -- to conduct groundbreaking research and development, rigorous safety studies, and extensive human trials to establish meaningful uses of their medical technologies, the majority of their studies occur overseas where they are sure to receive swifter review and eventual approvals.

Read more:
Patient Beware: When Stem Cells Harm

On Nutrition: Sugar Questions

By Barbara Quinn Print Article

(MCT)As we wind down National Nutrition Month, this question from a reader deserves attention:

Please help me. My husband and I are trying to do a no-sugar (diet) but we are confused. Everything we eat has sugar in it. Is it OK to eat natural sugar when we are trying to do no sugar? Like the plain Greek yogurt has sugar, so do we NOT eat it or is this OK? And we eat the Ezekiel bread which also has sugar. Is this OK? It seems like everything has sugar. When they mean no sugar are they saying no added sugar or refined sugar or just stop eating yogurts and fruit? Very confusing. Thank you. Rubie G.

Dear Rubie,

Very confusing indeed.

Sugar is the energy plants produce from being exposed to the sun. So natural sugar usually refers to sugar as it comes directly from nature. For example, sucrose (a two-part sugar made of one part glucose and one part fructose) is found naturally in sugar beets and sugar cane and other fruits, vegetables and grains. Fructose is the primary sugar in fruit, honey and agave.

Lactose is the natural sugar in milk and yogurt. (Yes, I know cows are not plants. Cows eat plants, however, and produce milk which contains lactose, or milk sugar.)

Is it OK to eat natural sugars? Unless you have a medical condition that excludes any of these foods, the sugars derived from fruit, vegetables, grains, milk, and yogurt provide the main energy source for your brain, nerves and muscles. And these sugars come conveniently packaged with an array of vitamins, minerals and other life-sustaining nutrients.

Sugar derived from fruit, vegetables and grains can be also be refined into crystals and other forms for us to conveniently use in cooking, baking or to sweeten our coffee or tea. These are collectively known as added sugars. Sucrose (what we call table sugar), molasses, maple and corn syrups are examples of added sugars.

Sugar has many redeeming values. It gives flavor to food (babies get their first taste of sugar from moms milk). Sugar feeds yeast which helps bread rise. It holds moisture, gives tenderness and helps brown baked goods. Not surprising, then, that Ezekiel bread contains some sugar added to the recipe.

See original here:
On Nutrition: Sugar Questions

Idaho Technology Launches FilmArray(R) Respiratory Panel at European Congress of Clinical Microbiology and Infectious …

Idaho Technology Launches FilmArray(R) Respiratory Panel at European Congress of Clinical Microbiology and Infectious Diseases

Idaho Technology Inc.

02.04.2012 09:00

Establishes Distribution Network to Market in Europe

SALT LAKE CITY, 2012-04-02 09:00 CEST (GLOBE NEWSWIRE) -- Idaho Technology, Inc., a privately held biotechnology and clinical diagnostics company dedicated to providing the world's fastest, highest-quality instruments for pathogen identification and DNA analysis, today announced the European launch of its FilmArray Respiratory Panel (FilmArray RP), a multiplex clinical diagnostic product that simultaneously detects 21 respiratory pathogens in about one hour. FilmArray RP is Idaho Technology's first clinical diagnostic test designed to run on the Company's user-friendly FilmArray system. The FilmArray RP received FDA 510(k) clearance last year for a panel of 15 analytes and recently achieved CE in vitro diagnostic (IVD) registration in the E.U. for a panel of 21 analytes.

The Company also announced that it is partnering with the DiaMondiaL family of distributors in strategic territories throughout Europe. Each of these partners is well recognized as a leading supplier of laboratory instruments and testing services, and will now add FilmArray RP to their product offerings.

The product is being showcased at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), held March 31 - April 3, 2012, at ExCeL London, London, UK (Booth 567).

'Launching FilmArray RP in Europe represents a significant milestone for our clinical diagnostics business,' said Kirk Ririe, Chief Executive Officer of Idaho Technology. 'Along with our esteemed distribution partners, we are pleased to offer our user-friendly multiplex pathogen detection system to the broad community of clinical laboratory professionals. Our FilmArray system is capable of testing for a comprehensive panel of viral and bacterial pathogens in about one hour, while offering the user only two minutes of hands-on time, with no precise measuring or pipetting required. We believe this represents a significant advancement in the field of infectious disease detection, with the potential to improve the testing capacity of hospital clinical laboratories worldwide.'

Since launching in the U.S., FilmArray RP has experienced rapid adoption by the clinical laboratory community. In January 2012, Idaho Technology filed a submission with the FDA to clear five additional respiratory pathogens in an expanded panel for use on the FilmArray system. The Company expects to receive FDA clearance for the expanded panel in the second quarter of 2012. Idaho Technology is continuing to develop a broader test menu for its FilmArray system, including a blood culture ID panel, gastrointestinal panel, and an STI panel.

About FilmArray RP

Original post:
Idaho Technology Launches FilmArray(R) Respiratory Panel at European Congress of Clinical Microbiology and Infectious ...

How long will you live? Just crunch the numbers

carly weeks From Monday's Globe and Mail Published Monday, Apr. 02, 2012 12:01AM EDT Last updated Monday, Apr. 02, 2012 6:38AM EDT

Want to know how long youll live? A new online longevity calculator may have the answer.

The calculator, created by Ontario scientists, asks questions about a persons smoking, drinking, eating, physical activity and other factors to predict his or her lifespan.

Although there are many similar tools online, this calculator is based on real data on factors contributing to deaths in Ontario.

The calculator was created as part of a new report published Monday that found 60 per cent of deaths in Ontario are linked to five controllable lifestyle factors: smoking, alcohol, diet, physical activity and stress.

I was taken aback, even though I work in this field, said Doug Manuel, lead author of the report and senior scientist at the Institute for Clinical Evaluative Sciences and the Ottawa Hospital Research Institute.

If people changed even one bad habit, they could gain several years of life, according to the report published online Monday by the ICES and Public Health Ontario.

For the report, researchers examined responses from Ontario health surveys, which question people about habits, such as diet. Using a database at ICES, they were able to see what happened to survey respondents over time and the age at which they died, helping them determine the relationship between health risk factors and longevity.

Dr. Manuel and his colleagues decided to create the life expectancy calculator as a tool to help Ontarians see how their lifestyle may affect their health. Its available online at rrasp-phirn.ca/risktools.

The calculator doesnt guarantee accuracy and cant account for people with pre-existing medical conditions. But, in general, it reveals how behaviour, such as the amount of exercise you

View original post here:
How long will you live? Just crunch the numbers

Genetic Sensor Boosts Biofuel Production

Genetic Sensor Boosts Biofuel Production

Designer microbes regulate their own pathways to optimize fuel production, boosting yields threefold.

Give bacteria a bit of self-awareness and they can be smarter about producing biofuel.

That's the conclusion from researchers at the University of California, Berkeley who report a genetic sensor that enables bacteria to adjust their gene expression in response to varying levels of key intermediates for making biodiesel. As a result, the microbes showed a threefold boost to the yield of the fuel. Such a sensor-regulator system could eventually help make advanced biofuels more cheaply and bring them one step closer to being an economically viable replacement to petroleum-based products.

One issue that has limited the amount of biofuels that a microbe makes is an imbalance of the different biological ingredients, or precursors, used to make the final fuel product. In a study published this week in Nature Biotechnology, Jay Keasling, professor of chemical engineering and bioengineering at the University of California, Berkeley, and colleagues describe a biological sensor system that enables bacteria to regulate genes in its biofuel-production pathways according to the amount of certain precursors in the cell.

The researchers augmented a previously reported strain of engineered E. coli that creates biodiesel from two biological building blocksfatty acids and ethanol. Over the lifecycle of that strain, one precursor can be produced at a higher level than another, an inefficient and sometimes harmful situation.

"The pathways weren't in balance," says Keasling. "The cells were wasting resources producing one precursor at a higher level than another." What's more, he says, is that biofuel production would sometimes consume too many fatty acids, which the bacteria need at certain stages of their life cycle, making the strain unstable.

Keasling and coworkers designed a microbe, using a naturally occurring sensor, that responds to the amounts of internal fatty acids and related molecules and tunes the activity of its pathways accordingly. When limited amounts of fatty acid are in the cell, the sensor-regulator molecules puts the brakes on both the ethanol-producing pathway and the fatty acid-converting pathway. Conversely, when the bacteria contain higher levels of fatty acids, the brakes on these pathways are released.

The sensor-regulator system improves the engineered bacteria in two ways, says Keasling: the metabolic pathways are better balanced so that one precursor isn't overproduced relative to the other and the modified bacteria are more stable because the biofuel production isn't robbing the cell of the ability to grow. This "self-awareness" increased the amount of biodiesel made by the bacteria to 28 percent of theoretical maximum, a three-fold increase over the previously reported strain.

Although the improvement is significant, biodiesel production is still too limited to bring the fuel into the mainstream. "There are many issues, including metabolic imbalances, that need to be solved to make biofuels a reality," said Keasling in an email. For instance, expanding these largely experimental cultures to commercial scaleon the order of a million literswill be a challenge.

Continued here:
Genetic Sensor Boosts Biofuel Production

N.Y. Preschool Starts DNA Testing For Admission

iStockphoto.com

At the Porsafillo Preschool Academy, there are 32 spots but more than 12,000 applications.

For years, New York parents have been applying to preschools even before their youngsters are born. That's not new, but the approach one prestigious pre-school on the Upper West Side is.

At the Porsafillo Preschool Academy, all applicants must now submit a DNA analysis of their children.

The preschool is housed in a modern glass and steel building designed by IM Pei. It's situated in a leafy corner of the Upper West Side. On a recent afternoon, Headmaster Rebecca Unsinn showed off "Porsafillo Pre," as it's called.

"Over here, we have computer labs, C++ learning, which of course, as I'm sure you know, is a language of computers," she says. Wait, computer language? These preschoolers are learning C++?

"Oh, absolutely they are," Unsinn says. "And they're very good at it."

That's not the only language they're learning; all the children are also enrolled in a Mandarin Chinese immersion program.

More than 12,000 applications pour into Unsinn's office each fall. That's 12,000 hopefuls for just 32 spots a year. It makes Porsafillo Pre the most competitive preschool in the United States.

So in a bid to weed out the kids who have no chance, the school decided to require a DNA test for all applicants. Before she joined the school in 2009, Unsinn was a child neurologist. She was hired specifically to implement this new policy.

Read the original post:
N.Y. Preschool Starts DNA Testing For Admission

Posted in DNA

DNA sequencing lays foundation for personalized cancer treatment

ScienceDaily (Apr. 1, 2012) Scientists at Washington University School of Medicine in St. Louis are using powerful DNA sequencing technology not only to identify mutations at the root of a patient's tumor -- considered key to personalizing cancer treatment -- but to map the genetic evolution of disease and monitor response to treatment.

"We're finding clinically relevant information in the tumor samples we're sequencing for discovery-oriented research studies," says Elaine Mardis, PhD, co-director of The Genome Institute at the School of Medicine. "Genome analysis can play a role at multiple time points during a patient's treatment, to identify 'driver' mutations in the tumor genome and to determine whether cells carrying those mutations have been eliminated by treatment."

This work is helping to guide the design of future cancer clinical trials in which treatment decisions are based on results of sequencing, says Mardis, who is speaking April 1 at the opening plenary session of the American Association for Cancer Research annual meeting in Chicago. She also is affiliated with the Siteman Cancer Center at the School of Medicine and Barnes-Jewish Hospital.

To date, Mardis and her colleagues have sequenced all the DNA -- the genome -- of tumor cells from more than 700 cancer patients. By comparing the genetic sequences in the tumor cells to healthy cells from the same patient, they can identify mutations underlying each patient's cancer.

Already, information gleaned through whole-genome sequencing is pushing researchers to reclassify tumors based on their genetic makeup rather than their location in the body. In patients with breast cancer, for example, Mardis and her colleagues have found numerous driver mutations in genes that have not previously been associated with breast tumors.

A number of these genes have been identified in prostate, colorectal, lung or skin cancer, as well as leukemia and other cancers. Drugs that target mutations in these genes, including imatinib, ruxolitinib and sunitinib, while not approved for breast cancer, are already on the market for other cancers.

"We are finding genetic mutations in multiple tumor types that could potentially be targeted with drugs that are already available," Mardis says.

She predicts, however, that it may require a paradigm change for oncologists to evaluate the potential benefits of individualized cancer therapy. While clinical trials typically involve randomly assigning patients to a particular treatment regimen, a personalized medicine approach calls for choosing drugs based on the underlying mutations in each patient's tumor.

"Having all treatment options available for every patient doesn't fit neatly into the confines of a carefully designed clinical trial," Mardis acknowledges. "We're going to need more flexibility."

When during the course of cancer mutations develop also is likely to be important in decisions about treatment. In a recent study, Mardis and her team mapped the genetic evolution of leukemia and found clues to suggest that targeted cancer drugs should be aimed at mutations that develop early in the course of the disease.

Excerpt from:
DNA sequencing lays foundation for personalized cancer treatment

Posted in DNA

L.A. County Science Fair names top student scientists

Judges at the Los Angeles County Science Fair named the top two winners of the competition on Saturday out of the more than a thousand students who had their experiments on display.

Kenneth Lee, a senior from Palos Verdes Peninsula High School, received the top sweepstakes prize for the senior-level division made up of high school students. He won for his project in the biochemistry and molecular biology category: "The Role of Testosterone in Hepatocyte Apoptosis in High Fat Diet-Induced Non-Alcoholic Fatty Liver Disease." His teacher on the project was Peter Starodub.

At the junior level for middle-schoolers, Raymond Gilmartin, an eight-grader at South Pasadena Middle School, took the sweepstakes prize. He had a project in the physics-aerodynamics and hydrodynamics category: "Spare the Environment, Spoiler the Car." His teacher on the project was Emily Hoffman.

Judges also awarded first-, second- and third-place medals, as well as honorable mention prizes, in a number of other categories, with animal physiology and biology, behavioral science, biochemistry and molecular biology, chemistry, engineering and mathematics and computer science, among them.

An exhibit hall at the Pasadena Convention Center was lined with rows of tri-fold poster boards featuring the projects, some of which will proceed to a statewide science fair and then on to the international level.

The science fair, in its 62nd year, had more students involved than in recent years, with 1,063 students taking part. The students came from public and private schools, as well as from those of the Archdiocese of Los Angeles. The number of girls participating has eclipsed the number of boys in recent years a trend that continued this year with 564 girls and 499 boys.

ALSO:

Rescue attempt underway for injured on yacht off San Francisco

Mega Millions: California jackpot winners have not come forward

Visit link:
L.A. County Science Fair names top student scientists

Who/What's new

WHO'S NEW/PROFESSIONAL DEVELOPMENT

Daytona Beach

Dr. Carol Gaines has joined the medical staff of Florida Hospital Memorial Medical Center. She previously worked with the Ohio University College of Osteopathic Medicine in Athens, Ohio, and more recently, with Winn Army Community Hospital, Ft. Stewart.

Ormond Beach

Jim Theriault has joined the sales staff of The Door Store a company that specializes in doors, screens, windows and hurricane panels. He worked in the window and door business for 40 years and formerly worked at Dunns Lumber in Daytona Beach.

Palm Coast

Dr. Ryan Smith has joined Flagler Dental Associates. He earned a master's degree in biomedical science at Nova Southeastern University and graduated from the university's College of Dental Medicine. He is a member of the American and Florida Dental Associations, the Academy of General Dentistry and American Society of Forensic Odontology.

Ana DeAlmeida, a Realtor with Exit Realty First Choice, has been recognized by Exit Realty Florida as a top producing associate for the state of Florida for the month of February. She ranked fifth statewide for the company in representing the buyer's side in real estate transactions.

Sheila K. Benn is the new executive director of the Windsor of Palm Coast, an assisted living community. She is a licensed practical nurse and has 11 years of geriatric experience.

Port Orange

Go here to see the original:
Who/What's new

Charity Soccer Tournament:

The UA Women's Club Soccer Team, with the support of Campus Rec and Honors Student Council, is putting on a barefoot 3v3 charity soccer tournament to benefit Grassroot Soccer (GRS). All of the proceeds from this event will go straight to GRS--an awesome NGO that uses soccer as a platform to gather and educate kids in Sub-Saharan Africa about HIV/AIDS. Just $25 can provide one child with the knowledge and life-skills to remain HIV-free. Check out grassrootsoccer.org for more information about their work and success in Africa.
Come play in our 3v3 tournament on April 7 from 11-4 on the Mall to help the cause. It's only $10 to sign up or $20 gets you an awesome Grassroot Soccer dry fit jersey in addition to a spot in the tournament. Gather a team of up to 5 of your friends (3 players minimum) and come join the fun! No soccer experience is necessary!! There will be prizes for winners, music, and plenty of free food.
Sign up at: https://grassrootsoccer.wufoo.com/forms/university-of-arizona-3v3-soccer-tournament/
Visit the Facebook page at: http://www.facebook.com/events/324097504305121/
For more information feel free to contact Aubri Carman at acarman25@gmail.com.
Thanks for your support!

Source:
http://physiologynews.blogspot.com/feeds/posts/default?alt=rss

Leica Microsystems Introduces Tissue IA 2.0* Quantitative Image Analysis Fluorescence and Brightfield Analysis for Digital Pathology

This morning Leica announced the release of a new image analysis application desgined to integrate with their portfolio of the SCN400 scanner and Ariol technology.  Was able to get a sneak peek at this application recently and was impressed with ease of use and accuracy embedded within a complete digital pathology solution from scanning to archiving to viewing to image analysis.  

As frequent readers know, I consider image analysis a significant component of digital pathology.  The technology takes pathology to a place we have not enjoyed with conventional microscopy and often single stains on a single slides, usually immunohistochemistry-only or flourescent-stain alone.  

While effective, it limits interpretation largely to tumor biology rather than cellular biology. Image analysis allows for deconvoluting multiplex staining to ask very specific questions about particular cellular phenotypes rather than tumor phenotypes, and in return, answer some specific questions related to celliular behavior, clinical prognosis & enhance biomarker development and drug discovery.

Lessons learned from the HER2 experience, related therapy and known issues with processing, staining and interpretation I think have shown the need for image analysis for improved accuracy, consistency and reproducibility.

Wetzlar, Germany, March 30, 2012—Leica Microsystems announces the release of Tissue IA 2.0, high performance image analysis for discovery research. Combining fluorescence and brightfield analysis capabilities in a single platform, with precision cell modelling, Tissue IA 2.0 offers a superior solution for IHC biomarker quantification. Tissue IA 2.0 joins the Total Digital Pathology portfolio from Leica, providing streamlined end-to-end excellence in capture, management and analysis of digital pathology images.

Single screen no arrows Tissue IA 2 maskA major challenge in research today is retrieval of quantitative, reproducible data from tissue-based IHC studies. Tissue IA 2.0 provides expert tools for researchers to extract the most from their studies. Powerful color separation and multi-marker colocalization functionality provides advanced insight and unbiased measurement of multiple antigen immunostaining in brightfield or fluorescent samples. Sophisticated cell modelling accurately detects and quantifies differential expression of staining in cellular compartments, providing detailed insight into cytoplasmic, membrane and nuclear biomarker localization.

The advanced dual staining capabilities in Tissue IA 2.0 enable researchers to identify cell cohorts at the molecular level.  Use one marker to identify a population of interest and then quantify expression of a second, providing exceptional analysis performance and greater understanding of a user’s slides.  Algorithms are easily adjusted and optimized for different markers, tissue and protocols giving a flexible platform for drug discovery applications. 

Easy to deploy and easy to use, the Tissue IA web-accessible interface means that users can take their analysis with them wherever they go. With high throughput batch analysis capacity, Tissue IA 2.0 will process whole slides, regions of interest or tissue microarray cores, and automatically integrate analysis results with a user’s slides. A built-in upload interface facilitating integration of algorithms from 3rd party software solutions, gives greater flexibility to further expand analysis options.

Dr. Donal O’Shea, Head of Digital Pathology in Leica Microsystems, says:

“Mulitplexing is of growing importance in translational research and tools to help quantify the expression and location of multiple biomarkers concurrently in tissue are a real requirement.  TissueIA 2.0 delivers for the user through offering chromogenic and fluorescence quantification and co-localization, cell based histoscoring on multi-compartmental IHC staining and the power to include and exclude cell populations based on biomarker expression.  In conjunction with our SCN400 F and Ariol platforms, this further expands our Digital Pathology portfolio for the life science and clinical researcher and demonstrates our ongoing commitment to this area.”

Tissue IA 2.0, with its powerful, streamlined analysis, is the ideal choice for biomarker discovery and translational research. Its unique combination of flexibility, automation and ease-of-use make it an unparalleled tool for digital pathology research. To learn more about Tissue IA 2.0, please visit http://www.leica-microsystems.com/products/digital-pathology/analyze/details/product/tissue-ia/

Leica Microsystems will be at the American Association for Cancer Research Annual Meeting 2012, March 31 – April 4, Chicago, IL. Visit Leica at booth 4103 to experience our new image analysis solution for Digital Pathology.

*For research use only. Not for use in diagnostic procedures.

About Leica Microsystems

Leica Microsystems is a leading global designer and producer of innovative, high-tech, precision optical systems for the analysis of microstructures. It is one of the market leaders in each of its business areas: Microscopy, Confocal Laser Scanning Microscopy with corresponding Imaging Systems, Specimen Preparation, and Medical Equipment. The company manufactures a broad range of products for numerous applications requiring microscopic imaging, measurement, and analysis. It also offers system solutions for life science including biotechnology and medicine, research and development of raw materials, and industrial quality assurance. The company is represented in over 100 countries with 16 manufacturing facilities in 9 countries, sales and service organizations in 19 countries and an international network of dealers. The global management is headquartered in Wetzlar, Germany.

 

Source:
http://feeds.feedburner.com/DigitalPathologyBlog

Driving Mr. Albert to Philadelphia and beyond

One of my all-time heroes as a child was Albert Einstein.  Regarded as one of the greatest minds of the 20th century if not civilization itself, he had an incredible personal story, professional triumphs and personal tragedies.  I used a quote of his to begin my essay for medical school: "“Imagination is more important than knowledge. For knowledge is limited to all we now know and understand, while imagination embraces the entire world, and all there ever will be to know and understand.

There are dozens of other great quotes attributed to him, including "We can't solve problems by using the same kind of thinking we used when we created them" or "Logic will get you from A to B.  Imagination will take you everywhere".

Perhaps my favorite one is attributed to Einstein while helping a group of school-aged children with their math studies: "Do not worry about your difficulties with mathematicss; I can assure you mine are much worse".

Over 10 years ago a book was published entitled Driving Mr. Albert written in first person with someone who drove across America with Einstein's brain and the pathologist who for years had kept it in formalin. In addition for the trip, he talks about the problems associated with keeping wet tissue and the pathologists' problems, issues, paranoias and difficulties for doing so for decades.

Death_headlineEinstein died in 1955 at Princeton University due to a ruptured aortic aneurysm.  At the time he became ill he was offered surgery by a Dr. Nissen (I gather of Nissen fundoplication) to repair the aneurysm.  He refused.  The treatment offered to him at that time was a vascular graft, still experimental at the time, but an improvement over the standard therapy in early studies.  The other treatment was wrapping the aneurysm in saran wrap.  Grafts are standard of care today unless interventional radiology does it less invasively today by other means.

Anyways, looks like a trip to Britain is order as sections of the much talked about brain of Einstein will be on public display, news to me thanks to The Pathology Blawg.  Read more here.

Source:
http://feeds.feedburner.com/DigitalPathologyBlog

Daily Scan highlights of USCAP 2012 & Release of ePathViewer

6a00d834203d1f53ef0168e9249711970c-800wiOnce again, Ole Eichorn, Aperio's Chief Technology Officer and The Daily Scan blogger put together a nice photo montage with captions and highlights from this years USCAP meeting exhibit floor.  In addition to showcasing Aperio's booth and products, Ole highlights many other companies, their products and how many other vendors are using digital pathology or services that tie into digital pathology.

Aperio also released their ePathViewer for iPad last week.  Was able to get a sneak peak at this from some Aperio folks earlier this month and is a must have for whole slide afficiendos. Reviewed some Juan Rosai collection slides as well as some SecondSlide cases with the app and despite a slow network the image refresh rate (and quality) were excellent (pre getting my iPad3 with HD display).

Below the screen shot below on the App Store you can also see other iPad viewers for viewing other whole slide images from Leica, Motic, Objective Pathology & large medical images with cool names like WholeSlide, iPathology and SlidePath.

Is was not so long ago that digital pathology relied upon being tethered to a desktop PC with enough RAM and bandwidth to view the images.  

No more.  Digital pathology is mobile!

The days of being tethered to your histology laboratory, your microscope and your laboratory information system (thanks to web-based LISs) are over.  

Mzl.tavubxcg.480x480-75


Source:
http://feeds.feedburner.com/DigitalPathologyBlog

Next-Generation Pathology – Webinar this Thursday

Next-generation Pathology

Pathology faces increasing competition from the modern methods of molecular biology. Genomics and proteomics promise to provide unbiased, quantitative data revealing insights into origin and progression of disease. Will pathology need to change in order to defend its territory? Quite certainly. Should pathologists forget what they have learned over the centuries? I don’t think so.

It could be claimed that the basic pathological methods have changed too little since the invention of the light microscope. However, the basic reason to look at histological samples didn’t change either. The morphological details of heterogeneous tissue provided invaluable information well before genes and proteins were discovered. And they continue doing so ever since.

Genes and proteins are essential components of the molecular magic that brings about tissue morphology (among other things). No biological science can afford ignoring all we have learned about them in the recent past. At the same time, genetic fingerprints and protein profiles are mostly obtained from blood or homogenized tissue samples that lack the spatial dimension histology is all about.

Tissue slides reveal the complex interplay between different cellular populations, their gene expression levels and metabolic status. They thus are a more comprehensive readout of molecular dynamics than any molecular technique alone could ever provide. Pathological scores, though, are necessarily less comprehensive. They aim at reducing complexity in order to increase consistency. They are so successful at achieving the former, that the quantitative requirements of modern science are hardly met. Yet they often fail to establish the latter as inter-observer variation remains high.

Next generation pathology will need to integrate molecular techniques into the traditional framework of histology: the morphological complexity of heterogeneous tissue. The required methods are well established and they are now transforming pathology. Immunohistochemistry combines molecular information on protein levels with spatial context. Novel methods based on in situ hybridization are reaching the maturity required to complement the histological toolbox. One by one, IHC stains put proteins into context. SISH, CISH, FISH et al. now do the same with genes. These advances open another dimension to the information that can be derived from histological samples. The spatial dimensions can be complemented with molecular ones. And the molecular information can be added to the information residing in tissue instead of competing with it.

As usual, the next generation comes along with novel toys. Automated image analysis is required to capture the quantitative readouts promised by the molecular advances. In order to go beyond genomics and proteomics, pathological knowledge will have to be accounted for and it is thus essential to make the novel approaches available to pathologists. To get from toys to tools, automated image analysis solutions need to be straightforward enough to be used routinely by pathologists. At the same time, they need to be flexible enough to robustly cope with the heterogeneity of histological samples.

Tissue proteomics and tissue genomics should be the pathologist’s reply to the molecular challenge they face.

For more information on this, check out Definiens Webinar series, including one this Thursday entitled "Quantitative Digital Pathology Out-of-the-Box: Definiens Tissue Studio Combines Flexibility and Ease-of-Use with High Productivity". Click here to register.

Thursday March 29th, 2012

Get an introduction to the straigthforward configuration of image analysis solutions with Definiens Tissue Studio. With no more than a few clicks, you can assemble a solution that is adjusted to the specific properties of your tissue sample and that provides you with the quantitative readouts you require. Per region of interest. Per cell. Per cell compartment. Definiens Tissue Studio readily analyzes images from any solid tissue, stained with IHC, H&E or IF. 

Date: Thursday, March 29
Time: 4 pm CEST / 10am EDT / 7am PST

Click here to register.


Source:
http://feeds.feedburner.com/DigitalPathologyBlog

CBLPath Receives Approval From New York State Department of Health for XALKORI(R) Companion Diagnostic

CBLPath recently announced it is one of a select few labs within the United States to offer Vysis(R) ALK Break Apart fluorescence in situ hybridization (FISH) testing for non-small cell lung carcinoma (NSCLC). The Vysis ALK FISH test detects rearrangements in the ALK gene employing fluorescent probes to detect the presence or absence of specific DNA sequences.

Vysis ALK FISH is the only FDA-approved companion diagnostic for XALKORI(R) (crizotinib). XALKORI was recently approved under the FDA's priority review program for treatment of patients with late-stage NSCLC who have an abnormal ALK gene. XALKORI has been shown to inhibit the proliferation of ALK, thereby suppressing growth of NSCLC tumors.

"CBLPath is proud of the positive impact our work has on patients' lives," said Chief Medical Officer, Dr. Carlos D. Urmacher, FCAP, FASCP. "Keeping at the forefront of the latest technologies ensures our clients and their patients have access to the best therapies available. By receiving approval from New York State to run the Vysis ALK FISH test, we are able to help clinicians identify those patients who will benefit from treatment with XALKORI."

Non-small cell lung cancer is the most common type of lung cancer with approximately 170,000 new cases per year in the United States. Non-small cell lung cancer includes adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. There are a variety of treatment options for NSCLC, and a patient's success with any treatment option is dependent upon their genetic profile. About 1-7% of patients with NSCLC possess the ALK gene abnormality. These patients are typically young and non-smokers. Patients with the ALK mutation respond favorably to treatment with XALKORI.

XALKORI is a registered trademark of Pfizer Inc. Vysis is a registered trademark of Abbott Laboratories.

Full press release.

Source:
http://feeds.feedburner.com/DigitalPathologyBlog

Panoramas! Baroque TV Evangelism! Human Zoos! Frederik Ruysch! Religious Theatre! Announcing the 2012 Congress of Curious Peoples Lineup!


I am SO very excited to (finally!) announce the lineup for this years' Congress of and for Curious Peoples, taking place this April 13-22 at Coney Island USA!

For those of you new to the concept, The Congress of Curious Peoples is a 10-day series of lectures and performances devoted to curiosity and curiosities broadly considered. If features sideshow acts, lectures, performances, and a 2-day scholarly-yet-popular symposium called The Congress for Curious Peoples, which is produced by The Morbid Anatomy Library in tandem with The Coney Island Museum.

This year's Congress for Curious Peoples symposium will feature panel discussions on such topics as pre-cinematic immersive amusements and religion as spectacle, while some of the featured speakers will be Sara Velas of The Velaslavasay Panorama; Paul Koudounaris of Empire of Death; an as-of-yet unnamed representative of the amazing Sleep No More; and Colin Dickey, author of Cranioklepty. Also featured will be stand-alone lectures on the 17th century artist of fetal skeleton tableaux Frederik Ruysch and the phenomenon of ethnographic displays called "human zoos," a screening of an over-the-top early 1970s TV Evangelist Christmas spectacular, and introductory lectures by myself and Coney Island Museum director Aaron Beebe.

Full lineup below; hope to see you at some--if not more--of the terrific events making up this year's Congress!

SYMPOSIUM: THE 2012 CONGRESS FOR CURIOUS PEOPLE
Saturday and Sunday, April 21st and 22nd

SATURDAY APRIL 21st

11:00 – 12:00: Keynote Addresses

12:00 – 1:00: Lunch

1:00 – 3:30: Immersive Amusements: Cosmoramas, Cycloramas and Panoramic Illusions: Panel discussion moderated and introduced by Aaron Beebe, The Coney Island Museum

4:00 – 5:00: The Business of the Dead: Frederik Ruysch as an Entrepreneurial Anatomist, Lecture by Daniel Margocsy, Hunter College

5:00: Christmas in America: Miss Velma and the Evangelist Spectacle: Screening of “Christmas in America,” an early 1970s television special by Miss Velma, early TV evangelist, introduced by Daniel Paul

SUNDAY APRIL 22

11:00 – 1:00: Religion and Spectacle: A panel with discussion moderated and introduced by Joanna Ebenstein, Morbid Anatomy Library

1:00 – 2:30: Lunch and Sideshow Visit

2:30 – 3:30: Traveling Ethnographic Shows and Human Zoos, a lecture by Elizabeth Bradley

3:30 – 5:30: Theater Rethunk: An Alternative History of the Theatrical: A panel with discussion moderated and introduced by Chris Muller

And now, for the full 10-day Congress Schedule:

Friday, April 13
Opening Night Party featuring The Lizard Man and the annual inductions into the Sideshow Hall of Fame.

Saturday, April 14
Alumni Weekend at Sideshows by the Seashore (Continuous Admission, Tickets at the door); Colonnade of Curiosities in the Freak Bar.

Sunday, April 15
Alumni Weekend at Sideshows by the Seashore (Continuous Admission, Tickets at the door); Colonnade of Curiosities in the Freak Bar

Monday April 16th
7:30 – (Lecture) Amy Herzog: Architectural Fictions: Economic Development, Immersive Renderings, and the Virtualization of Brooklyn
9:00 – (Performance) Shea Love and the Circus Emporium

Tuesday April 17th
7:30 – (Lecture) Philip Kadish: “Pinhead Races and the White Man’s Burden”
9:00 – (Performance) The Squidling Bros Sideshow

Wednesday April 18th
7:30 -(Lecture/Performance) ‘An Evening of Fate, Chance and Mystery’ with Lord Whimsy and Les the Mentalist
9:00 – (Performance) Jo Boobs

Thursday April 19th
7:30 – (Lecture/Performance) Erkki Huhtamo: “Mareorama Revisited”
9:00 – (Performance) The Curious Couple from Coney Island

Friday April 20th
7:30 – (Performance/Reading) “Venus,” a play by Suzan Lori Parks
9:00 – (Performance/Lecture) Sideshow Legend Jim Rose

Saturday April 21st
Super Freak Weekend at Sideshows by the Seashore (Continuous Admission, Tickets at the door); Colonnade of Curiosities in the Freak Bar
Congress For Curious People (Day 1 of a 2-day Symposium)

Sunday April 22nd
Super Freak Weekend at Sideshows by the Seashore (Continuous Admission, Tickets at the door); Colonnade of Curiosities in the Freak Bar
Congress For Curious People (Day 2 of a 2-day Symposium)

Tickets for the symposium are available here; for tickets to individual events and lectures, click here; 10-day Congressional Passes--which provide access to all events!--are available here. All events take place at 1208 Surf Avenue in Coney Island in Brooklyn, New York; you can map it here. See you there!!!

Source:
http://morbidanatomy.blogspot.com/feeds/posts/default?alt=rss